PTGS2 and autoimmune thrombocytopenic purpura: Although studies reported that selective COX-2 inhibitors such as celecoxib could lead to the activation of caspases in tumor cells [45, 46], no significant correlations were found between caspases and COX in ITP platelets, suggesting differences in physiological processes in different cells and different disease background.